Reference Detail

Ref Type
PMID
Authors Benjamin R. Tan, Joel Picus, Emily Chan, Albert C. Lockhart, Bruce J. Roth, Ashley Morton, Chris Liang, Andrea Wang-Gillam
Title Phase I study of X-82, an oral dual anti-VEGFR/PDGFR tyrosine kinase inhibitor, with everolimus in solid tumors.
Journal Journal of Clinical Oncology
Vol
Issue
Date
URL http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.2588
Abstract Text Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2588-2588

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Therapy Description
Vorolanib Vorolanib (X-82) is a dual VEGFR/PDGFR inhibitor, which inhibits tumor angiogenesis and cell proliferation in tumors (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2588-2588).
Drug Name Trade Name Synonyms Drug Classes Drug Description
Vorolanib X-82 PDGFR Inhibitor (Pan) 27 VEGFR Inhibitor (Pan) 30 Vorolanib (X-82) is a dual VEGFR/PDGFR inhibitor, which inhibits tumor angiogenesis and cell proliferation in tumors (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2588-2588).
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown renal cell carcinoma not applicable Everolimus + Vorolanib Phase I Actionable In a Phase I trial, combination of Vorolanib (X-82) and Afinitor (everolimus) resulted in partial response in 2 patients and stable disease in 1 patient with renal cell carcinoma (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2588-2588). detail...
Unknown unknown Advanced Solid Tumor not applicable Everolimus + Vorolanib Phase I Actionable In a Phase I trial, combination of Vorolanib (X-82) and Afinitor (everolimus) resulted in partial response in 9.5% (2/21) and stable disease in 57.1% (12/21) of patients with advanced solid tumors (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2588-2588). detail...
Unknown unknown neuroendocrine tumor not applicable Everolimus + Vorolanib Phase I Actionable In a Phase I trial, combination of Vorolanib (X-82) and Afinitor (everolimus) resulted in stable disease ranging from 3-23 months in 10 patients with neuroendocrine tumors (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2588-2588). detail...
Unknown unknown glioblastoma multiforme not applicable Everolimus + Vorolanib Phase I Actionable In a Phase I trial, combination of Vorolanib (X-82) and Afinitor (everolimus) resulted in stable disease in a patient with glioblastoma (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2588-2588). detail...